Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Delcia Rivas

1PUBLICATIONS

20CO-AUTHORS

Innate immunity

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Jan 23, 2025

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.

Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas

Pageof 1

Frequent Collaborators

1 joint publications

Anthony El-Khoueiry

1 joint publications

Omar Saavedra

1 joint publications

Jacob Thomas

1 joint publications

Claire Livings

1 joint publications

Elena Garralda

1 joint publications

Gabriele Hintzen

1 joint publications

Laura Kohlhas

1 joint publications

Dessislava Vanosmael

1 joint publications

Joachim Koch

1 joint publications

Erich Rajkovic

Frequent Collaborators

1 joint publications

Anthony El-Khoueiry

1 joint publications

Omar Saavedra

1 joint publications

Jacob Thomas

1 joint publications

Claire Livings

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos